Dr. Vanessa Zann, Vice President of Scientific Consulting, Translational Pharmaceutics^® and Clinical Pharmacology USA, contributes to Drug Development & Delivery's special feature on bioavailability & solubility. 

Dr. Zann says she has seen positive results with spray dried dispersion (SDD) formulations to help enhance fraction absorbed, which in turn increases exposure. Quotient Sciences uses biorelevant dissolution to rank solu­bility-enhanced technology platforms and then selects the most promising for clinical assessment.

“Note there is often a disconnect be­tween preclinical in vivo data and clinical outcomes,” she says. “We recommend as­sessing the SDD platform initially as a sus­pension formulation, which provides gold standard data for what is likely to be achieved with a good performing SDD tablet.”

For example, Tranquis approached Quotient Sciences in the preclinical stage to help develop clinical formulations for first in human (FIH). The compound in question was a BCS II compound (poor solubility and high solubility) and had shown solubility limited exposure preclini­cally, hence an enhanced formulation was anticipated to be required to achieve effi­cacious clinical exposures, explains Dr. Zann. Quotient Sciences used an inte­grated approach for drug product devel­opment, manufacturing, and clinical testing (this is the Translational Pharma­ceutics^® platform) to rapidly identify and overcome solubility and bioavailability challenges for this compound.

Three suspension formulations were developed for assessment in the FIH: a methylcellulose crystalline (MC) suspen­sion; a spray-dried dispersion (SDD) sus­pension; and a hot melt extrusion (HME) suspension. The regulatory package was filed with 90 days stability for the SDD and HME GMP intermediates and seven days for the powder in bottle (PiB). The suspen­sion had four hours in use stability and a rinsing trial performed on each to allow total dosing volume to be 240mL. She ex­plains that the SDD and HME both showed superior dissolution to the crystalline API in a biorelevant dissolution assessment, demonstrating a spring and parachute ef­fect with reduced precipitation in the intes­tinal phase. A number of SDD suspensions were also assessed in the rat prior to the FIH but didn’t show any improvement over the MC suspension.

The FIH study started dosing SAD co­hort 1 (60mg) and 2 (180mg) with a methylcellulose crystalline suspension, which gave three-fold higher exposure than anticipated from the preclinical species. At SAD cohort 3 (540mg), the subjects were initially dosed with the MC suspension, but then returned to the clinic for dosing with the SDD and HME suspen­sions. The dose of the SDD and HME sus­pension was reduced to 180mg to ensure that the exposure caps were not exceeded due to the already higher exposure in the clinic than originally predicted. The SDD had the highest exposure showing a four-fold increase compared to the MC suspen­sion. This formulation was selected for dosing the remainder SAD and MAD co­horts.

“The Translational Pharmaceutics^® platform allowed the study not only to de­liver safety, tolerability, and pharmacoki­netic data, but also formulation selection assessment ahead of Phase II patient tri­als,” says Dr. Zann.

Read the full article on Drug Development & Delivery's website here.

At DCAT 2025, Quotient Sciences showcased how using a fully integrated service provider can help optimize drug development.

In a video interview held just prior to the event, Helen Baker, Director of Formulation Design, discussed the benefits of having clinical, late-stage, and regulatory processes under one provider for benefits including better knowledge sharing and a more secure supply chain.

"A huge advantage of [having services under one umbrella] is that you cut out the white space that you often see between services as you move between them, as you go through the development process." Baker says in highlighting the Quotient Sciences Translational Pharmaceutics® platform—a disruptive approach to drug development that redefines the complementary, interconnected relationship between drug product design, supply and clinical testing.

"There's a single product manager … managing everything from start to finish. And it just simplifies the whole process, reduces that risk [of] what we already know is a very lengthy, costly and risky development process." she continued.

Watch Helen's full interview with BioPharm International

An investment of over $3 million to upgrade Quotient Sciences’ facility in Boothwyn, Pa. (Chelsea Parkway) was recently completed, making critical updates to the facility while also refreshing many of the facility’s cGMP manufacturing spaces and transforming previously underutilized areas into fully operational high potency suites.  

Converting two non-potent rooms into a state-of-the-art space that safely handles products up to PBLEC 4 has allowed teams at our Philadelphia Chelsea Parkway facility to increase efficiency and ability to manage more potent materials.  

The newly designed spaces include dedicated airlocks, showers, and cleaning rooms for handling HPAPI products to greater reduce risk of cross-contamination between suites. This allows for a more streamlined workflow, as dispensing operations and processing can occur in well-defined spaces, giving greater attention to safety and ensuring product quality.  

The enhancements better position our Chelsea Parkway facility to accommodate a range of PBLEC 5 products when new isolator equipment will be installed later this year. 

“Enhancements made to our Chelsea Parkway facility reflect our dedication to safety in high potency handling and making improvements to ensure that we remain a drug product manufacturing partner of choice for our pharma clients.” said Marlene Leuenberger, Vice President and General Manager of Quotient Sciences’ Philadelphia facilities.

Our ability to process potent APIs and share fewer common spaces with non-potent areas significantly lowers the risk of operational disruptions. Reconfiguring these spaces has allowed for a 20% increase in  capacity for HPAPI handling at the facility. 

The facility recently completed a successful inspection by the Chinese National Medical Products Administration (NMPA) in December 2024. It also has been recently inspected by agencies including the U.S. FDA, Japanese Pharmaceuticals and Medical Devices Agency (PMDA), Brazilian Health Regulatory Agency (ANVISA), and Russian Ministry of Industry and Trade. 

“We are dedicated to advancing our capabilities in the pharmaceutical manufacturing sector, particularly in high potency handling to greater meet the needs of clients working on oncology, orphan drugs for rare diseases, and other areas.” continued Ms. Leuenberger. “Recent improvements to operations at Chelsea Parkway allow us to better serve our clients while ensuring the highest standards of safety and compliance.” 

Quotient Sciences remains an innovator in drug product development and manufacturing. For more information about our drug product capabilities, which include commercial drug product manufacturing, visit our Drug Product web page.  

Get more details about our Boothwyn, Pa. (Chelsea Parkway) drug product manufacturing facility.

Quotient Sciences has been recognized as a finalist for a special category award, "Best Innovative Approach to Technology and Process Execution," in the 2025 CDMO Leadership Awards. This additional award nomination highlights our unwavering commitment to providing innovative solutions and exceptional service within the contract development and manufacturing organization (CDMO) sector.

Last month, Quotient Sciences was recognized as a 2025 CDMO Leadership Awards winner in the category of Small Molecule Dosage Form – Global, and a finalist for the opportunity to win a champion award in the same category. 

As part of the 2025 CDMO Leadership Awards, Outsourced Pharma asked the surveyed sponsors to identify top CDMOs in specific categories in order to determine these additional awards. The categories included: Best Scientific Expertise, Best On-Time Delivery, Best Seamless Delivery Across Phases, Best Innovative Approach to Technology and Process Execution, Best Manufacturing Capabilities, Best Facilities, Best Quality Management Systems. 

These categories created the new "Best In" awards for 2025 to recognize additional qualities sponsors value when selecting a partner. Nominees along with Quotient Sciences in the "Best Innovative Approach to Technology and Process Execution" category include:

• Quotient Sciences
• AGC Pharma Chemicals
• MilliporeSigma
• WuXi Biologics
• WuXi STA

The CDMO Leadership Awards recognize the best contract development and manufacturing organizations (CDMOs) across global and regional categories. Winners will be honored at an award ceremony taking place tomorrow in New York City.

The global OSD contract manufacturing market is projected to grow, however, the sector faces challenges and is constantly evolving.

According to industry experts, trends set to shape the industry include advancement in drug delivery technologies, the increasing focus on personalized medicine, an emphasis on sustainability, and consolidation within the CDMO sector, but by far the most pertinent change-maker on everybody’s radar is the rise of AI.

Dr. Andrew Lewis, Chief Scientific Officer, contributes to the roundtable conversation with Contract Pharma, adding, "The FDA reported that in 2021, it saw more than 100 drug and biologic application submissions containing elements of AI or machine learning (ML) used in the development process."

"The earliest applications of AI in the pharmaceutical industry were in drug discovery," says Lewis. "Now, applications are being found in almost every function throughout development—from report writing and investigation of quality events, to manufacturing process control and facility management."

Read the full article, OSD Manufacturing Market: Growth Trends & Outlook, on the Contract Pharma website.

How we conduct Translational Pharmaceutics® from our U.S. facilities and the difference that it makes in drug development 

For nearly 20 years, Quotient Sciences has been at the forefront of integrating contract research organization (CRO) and contract development and manufacturing organization (CDMO) solutions through Translational Pharmaceutics®. This pioneering approach merges operational efficiency, scientific rigor, and clinical insights into a seamless program—managed under a single organization with a dedicated program manager.

Collectively, we’ve completed more than 500 Translational Pharmaceutics® programs worldwide for more than 100 customers. While the Translational Pharmaceutics® platform has been used in the U.K. for over 17 years, Quotient Sciences has also been successfully running Translational Pharmaceutics® programs in the United States for over eight years, with significant growth and investment in recent years. 

Q&A with Dr. Helen Baker and Dr. Vanessa Zann on Quotient Sciences’ U.S. Translational Pharmaceutics® Capabilities

To discuss the evolution and impact of using Translational Pharmaceutics® programs to accelerate drug development for pharma and biotech clients in the U.S., we spoke with Dr. Helen Baker, Director of Formulation Design at Quotient Sciences, and Dr. Vanessa Zann, Vice President, Scientific Consulting, U.S. Translational Pharmaceutics® & Clinical Pharmacology.

Q: Translational Pharmaceutics® has been a core part of Quotient Sciences’ approach to drug development for nearly two decades. How has the U.S. offering evolved in recent years?

Dr. Baker: Our U.S. Translational Pharmaceutics® offering has developed significantly since we started our first programs, which are a partnership between our Philadelphia, PA and Miami, FL facilities to fully execute. Effectively, we have rebuilt our operations for Translational Pharmaceutics® in the U.S. to operate independently from traditional early and late-stage development or patient supply programs, such as clinical trial materials manufacturing.

Unlike traditional drug development, where drug product manufacturing and clinical testing are performed by entirely separate entities, Translational Pharmaceutics® maintains full control of the supply chain. Our CMC, quality, regulatory and clinical teams are fully integrated. 

Dr. Zann: Translational Pharmaceutics® requires a different way of working to conventional CDMO or CRO approaches. We have a dedicated team focused on U.S. Translational Pharmaceutics® and have expanded the capabilities of our U.S. sites to support Translational Pharmaceutics® projects that includes:

• Dedicated CMC and project management leadership
• Dedicated formulation, QA, and analytical support
• Expanded R&D lab spaces with cutting-edge equipment

Additionally, we’re coming up on the five-year anniversary of the expansion of our Miami pharmacy compounding capabilities. Our Miami site is a clinical pharmacology facility specializing in Phase I clinical studies but also contains an integrated research pharmacy department with the ability to perform sterile pharmacy compounding for the in-house Phase I clinic. This includes several formulation types, such as drug in capsule steriles for IV, IM and SC administration, solutions and suspensions. Compounding of non-sterile drug products is performed in accordance with USP<795>. Pharmacy compounding gives added flexibility in how we can manufacture drug product to support FIH trials at our Miami clinic.

Q: How does Translational Pharmaceutics® benefit drug developers when compared to traditional approaches?

Dr. Baker: Translational Pharmaceutics® streamlines drug development by integrating drug product formulation and cGMP manufacturing with clinical testing into a single program. 

Overall development timelines are accelerated and emerging clinical data is used to guide formulation and dose selection in real-time, improving decision making along the way. Translational Pharmaceutics® also allows for greater control of the supply chain and eliminates vendor management complexity for our clients when compared to having multiple, CRO and CDMO partners to coordinate.

Drug product batch sizes also have reduced stability requirements. We make smaller, 100- to 300-unit drug product batches with stability requirements of typically 7-14 days. The stability generated covers the clinical dosing period but also allows rapid progression into clinical testing and reduces API requirements. We don’t have a large batch of drug product manufactured and waiting to be dosed, at risk of being wasted if it is not needed. 

Dr. Zann: For most customers, we’ve seen Translational Pharmaceutics® save an average of 12 months of time in drug product development and Phase I clinical testing. When factoring in the extra steps, time, and cost removed from the lifecycle of a drug, the actual savings using Translational Pharmaceutics® can be far greater—as the Tufts Center for Drug Development saw when they conducted their assessment.

We know other providers offer programs to integrate similar services, but they are not replacements for what Translational Pharmaceutics® can offer. In all cases, we have found these to be separate programs of work, with separate project managers coordinating services. These programs are not nearly as integrated as a Translational Pharmaceutics® program, with the different teams and capabilities we assemble to make these possible. In addition, not all companies are able to see the formulation development through to the in vitro characterization and clinical outcomes—with Translational Pharmaceutics®, we can. 

Dr. Baker: With Translational Pharmaceutics®, everything is coordinated under one team, and there’s one program of work and one program manager who leads it. Our project managers are a lynchpin that make Translational Pharmaceutics® programs run the way they do, in the U.S. and in the U.K. They ensure that timelines are set and adhered to, monitoring client feedback along the way, so we can always ensure we are delivering against project milestones

Q: What investments have been made in the last 12-18 months to enhance Translational Pharmaceutics® capabilities in the U.S.?

Dr. Baker: We have made significant changes to our Philadelphia facilities (in Boothwyn and Garnet Valley, PA) to streamline our ways of working with dedicated teams and operational improvements as mentioned, which has taken place over the last year. Changes have also been made to what equipment and spaces are available for conducting U.S. Translational Pharmaceutics® programs to increase capacity and efficiency. Key investments include:

• Two dedicated R&D lab spaces for U.S. Translational Pharmaceutics® projects
• New equipment, including tablet presses, mills, and blenders and solubility enhancement technologies, including micronization and spray drying
• Semi-automated tablet presses, which has doubled our capacity compared to last year

These investments mean that we can develop and manufacture the full range of oral solid dosage forms—from simple, powder in bottle (PIB) formulations to more complex modified release formulations, or enabled formulations.

Q: How do Quotient Sciences’ U.S. Translational Pharmaceutics® programs support regulatory requirements?

Dr. Zann: Regulatory compliance is critical and our U.S. facilities have recently undergone successful regulatory inspections from multiple agencies, including the U.S. FDA, ANVISA (Brazil), and CFDI (China). This ensures that we can support both domestic and global development programs. 

Also, as part of a Translational Pharmaceutics® program the Quotient Sciences team will author the IND module 3 drug product section for the IND opening/update.

Q: Can you share examples of recent Translational Pharmaceutics® projects?

Dr. Baker: We’ve had many exciting Translational Pharmaceutics® projects, particularly in modified release formulation optimization and solubility-enhanced formulations. One standout program that we conducted as a Translational Pharmaceutics® project between our U.S. facilities was a first-in-human study for a top five global pharma company, where we developed a granulate-in-capsule formulation for a SAD/MAD and food effect study. Among the benefits included a three-month acceleration to the clinic and significant API savings. This program demonstrated the power of the Translational Pharmaceutics® platform by enabling real-time formulation refinements based on emerging clinical data.

Dr. Zann: We’re also proud of our recent work with Ensyce Biosciences, where a clinical program was completed in Miami, supported by our U.K. sites for drug product formulation development and manufacturing.

Lynn Kirkpatrick, the company’s CEO, approached us to address formulation challenges for their modified release product, PF614-MPAR, in development as a potential breakthrough in treating severe pain. After consulting a traditional CDMO, Ensyce Biosciences was told by that provider that it would take over 8 months for an initial drug product prototype. In Part 1 of the study, we assessed 10 different formulation combinations to identify the unit dose.

Realistically, the company would have faced years of development to optimize its formulation and determine the required dose for the PF614-MPAR drug product, if multiple iterations needed to be manufactured sequentially, and the traditional formulation development approach was undertaken.

We were able to complete the work in a fraction of the time that was quoted by the other provider. The company has since moved forward with Phase II/III trials and is scaling for commercial manufacturing. We are proud to see what the product will go on to achieve and the impact it may have in addressing the ongoing opioid crisis.

Q: Who benefits most from U.S. Translational Pharmaceutics® programs?

Dr. Baker: We work with a range of clients, from large pharma to emerging startups. The simple answer is that many clients can benefit from the time and cost savings that Translational Pharmaceutics® brings to early stage drug development. We’ve applied it across indications and patient groups - in drugs that are targeted for use in oncology, rare diseases, and pediatrics, just to name a few. 

We see many cases, like with Ensyce Biosciences, where clients want to move rapidly into formulation optimization in a more efficient, controlled way. 

We also see many clients who have limited API availability, or cases where it is very costly to produce. As I noted before, Translational Pharmaceutics® puts us in control of the full supply chain, including the amount of drug product needed - and thereby, API used - for a clinical study. Endevica was a peptide sterile formulation developed at Nottingham and then tech transferred to Miami for compounding, and according to the client due to small batch compounding with limited stability, the Translational Pharmaceutics model saved the client over 1 million dollars on the API synthesis cost. 

Having the flexibility to conduct Translational Pharmaceutics® programs in the U.S. can be particularly valuable when an organization has U.S.-based grant funding, for example from the National Institutes of Health (NIH). In nearly all cases, this mandates that studies must be conducted in the U.S. 

Dr. Zann: There are also significant benefits of using Translational Pharmaceutics® when a client has a challenging molecule, such as poor solubility or permeability. Our scientific team includes experts in formulation, biopharmaceutics, modelling and simulation, and clinical pharmacology so we can select the best strategy to overcome these challenges and design a development program to maximize the probability of success. 

Likewise, using Translational Pharmaceutics® is ideal when a client aims to develop a complex drug product, such as a modified release (MR) formulation or an oral peptide. The correlation between preclinical animals and humans for immediate release products can be poor (Grass and Sinko, 20XX) and in the case of MR or oral peptides can be even greater, therefore the opportunity to optimize these drug products based on  clinical testing with healthy volunteers is the preferred approach and likely to give the best opportunity for success.

Q: Can you tell me more about the wider team of scientific experts at Quotient Sciences? 

Dr. Baker: Globally, we have a group of very talented drug development experts and apply our experience across a range of areas. 
Ultimately, no matter where a customer chooses to work with us on a Translational Pharmaceutics® program, they benefit from our collective knowledge and an accelerated path to meet development milestones.

Meet the Team & Learn More at DCAT Week

For those interested in learning more about Translational Pharmaceutics®, we invite you to download our one-page summary to read more about the benefits of Translational Pharmaceutics®.